Nu-Life Unveils Nu-V3 5.0
September 2025, the Nu-Life team unveils its latest technology, Nu-V3 5.0. Recent advancements in micro-electronics, biocompatible materials, and medical grade 3D printing, has enabled Nu-Life to produce its final, go-to-market technology which is simple to apply, easy to use, and available
early in 2026.
Nu-V3 & NASA
Nu-Life has been invited and will submit detailed information for the use of Nu-V3 in space as well as pre-flight and post-flight applications.
Nu-Life & LSX Partner
Nu-Life Solutions has partnered with the LSX leadership creating a platform for creating awareness and demand for Nu-V3. Nu-Life will serve as Platinum Sponsor and Keynote Speaker in a host of in-person and virtual events over the next 24 months.
Nu-Life Japan Advances to Phase II
After completing our Phase I trial to determine usability and patient compliance, Nu-Life will now be delivering Nu-V3 5.0, for our Phase II trials and preparing for market entry in Japan, late 2026.
LSX Investival Event
Nu-Life Solutions CEO delivers the Keynote Address and leads the panel discussion, including indicators driving increased investment in neurotech.
Nu-Life Launches Webinar & Webcast Series
To compliment our LSX and CEO magazine events and appearances over the next 12 - 24 months, Nu-Life is launching the first in a series of webinars and webcasts, in cooperation with LSX and Informa Connect. The first webinar will take place on December 10th, 2025.
LSX Europe 2026
Nu-Life Solutions CEO addresses global expansion and pathways for Nu-V3 in 2026 and 2027. Nu-Life is also the Platinum Sponsor as Keynote Speaker throughout these LSX events.
​
"These LSX World Congress events set the stage for our market launch, 2026. The opportunity to assume a leadership role in these events over the next 24 months is quite an honor." ​ Jim Robertson
CEO - Nu-Life Solutions.
Back to the Top
